Lauren P. Silvernail Sells 52,015 Shares of Evolus, Inc. (NASDAQ:EOLS) Stock

Evolus, Inc. (NASDAQ:EOLSGet Rating) insider Lauren P. Silvernail sold 52,015 shares of the stock in a transaction dated Wednesday, May 18th. The shares were sold at an average price of $12.42, for a total value of $646,026.30. Following the transaction, the insider now directly owns 141,571 shares in the company, valued at approximately $1,758,311.82. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

NASDAQ EOLS opened at $12.33 on Thursday. Evolus, Inc. has a twelve month low of $5.06 and a twelve month high of $14.34. The firm has a 50-day simple moving average of $11.34 and a 200 day simple moving average of $8.58. The company has a current ratio of 3.51, a quick ratio of 3.42 and a debt-to-equity ratio of 1.06.

Evolus (NASDAQ:EOLSGet Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.24. The company had revenue of $33.90 million during the quarter, compared to the consensus estimate of $29.83 million. Evolus had a negative return on equity of 80.20% and a negative net margin of 58.28%. The company’s quarterly revenue was up 177.9% on a year-over-year basis. During the same quarter last year, the company earned $0.16 EPS. As a group, sell-side analysts expect that Evolus, Inc. will post -1.26 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in the company. Walleye Capital LLC bought a new position in shares of Evolus during the 1st quarter worth about $221,000. Worth Venture Partners LLC acquired a new position in shares of Evolus in the 1st quarter worth approximately $2,261,000. Point72 Hong Kong Ltd lifted its position in shares of Evolus by 979.7% during the 1st quarter. Point72 Hong Kong Ltd now owns 2,343 shares of the company’s stock worth $26,000 after buying an additional 2,126 shares during the period. First Manhattan Co. boosted its stake in Evolus by 22.5% in the 1st quarter. First Manhattan Co. now owns 4,084,938 shares of the company’s stock valued at $45,833,000 after buying an additional 750,022 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C acquired a new position in Evolus during the first quarter worth $13,792,000. Institutional investors own 36.94% of the company’s stock.

EOLS has been the topic of a number of recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 price target on shares of Evolus in a research report on Friday, March 4th. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Evolus in a research report on Friday, March 4th. Zacks Investment Research raised Evolus from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research report on Friday, May 13th. Barclays upgraded Evolus from an “underweight” rating to an “equal weight” rating and lifted their price objective for the stock from $8.00 to $10.00 in a research note on Thursday, May 12th. Finally, Truist Financial upgraded Evolus from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research note on Thursday, January 20th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to, Evolus has an average rating of “Buy” and a consensus target price of $14.50.

About Evolus (Get Rating)

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Articles

Insider Buying and Selling by Quarter for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with's FREE daily email newsletter.